Latest news with #VertexPharmaceuticals
Yahoo
2 days ago
- Business
- Yahoo
2 Top Stocks to Buy Right Now
Even in volatile times such as now, good stocks can be had if one looks carefully and thoughtfully. Berkshire Hathaway remains an attractive investment despite its upcoming leadership change. Vertex Pharmaceuticals has room to grow in its core market and continues to innovate in new areas. 10 stocks we like better than Berkshire Hathaway › Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks are likely to produce superior returns to most other assets over the next decade, as they have consistently done in the past. Moreover, when things are erratic, it can be a wise strategy to invest in companies that are positioned to perform well over the long term. Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). Warren Buffett's recent announcement that he would step down from his longtime role as the CEO of Berkshire Hathaway by the end of this year will almost certainly come down as one of the most talked-about pieces of news on Wall Street this year. In the wake of that leadership change, some investors may decide to steer clear of the stock. After all, it was Buffett who led the conglomerate to market-crushing returns over the decades, not Greg Abel, his chosen successor. Further, Buffett is leaving at an unsteady time economically. Corporations are facing a rapidly shifting global trade environment. Macroeconomic troubles appear likely to take a toll on many companies, even those as strong as Berkshire Hathaway. Can Abel successfully take the reins of the conglomerate, especially at a time like this? In my view, the answer is yes. Buffett might be irreplaceable, but he leaves behind an incredibly robust and diversified business. Between Berkshire Hathaway's several dozen subsidiaries across an array of sectors and industries, its impressive stock portfolio, and its massive cash stockpile, it's positioned to handle severe economic shocks better than most companies. Not all of the company's businesses will be affected equally by macro turbulence. Some might thrive as others suffer -- it will average out, at least somewhat. Berkshire Hathaway might not come out of a recession (if one is on the way) completely unscathed, but it will come out on solid footing. And regarding the pending change in management, Buffett did not pick Abel out of a hat. As a top executive of the conglomerate, Abel has soaked up Buffett's investment philosophy, and he has been capably overseeing a large portion of the company for years. Nor will Abel be doing the job alone, any more than Buffett did it by himself. Many of Berkshire Hathaway's executives have been with the company for a long time and have contributed significantly to it achieving its current status as one of the few corporations with a trillion-dollar-plus market cap. The stock should continue to deliver superior returns in the long run under new management. That's why it's still worth investing in today. Vertex Pharmaceuticals' shares recently plunged after it announced its fiscal second-quarter results. Those were unimpressive, partly due to a non-cash impairment charge it took relating to an investigational medicine it is no longer pursuing, and partly due to the illegal sales of knock-off versions of its patented drugs in Russia, which took a slice out of its total revenues. However, these are relatively minor issues, at least when viewed in the broader context. Vertex remains the undisputed leader in cystic fibrosis therapies. This rare lung disease only affects about 94,000 patients in Vertex's core markets of North America, Europe, and Australia. But since it sells the only medicines that target the underlying causes of the condition, Vertex has substantial pricing power. That's why revenue and earnings have consistently increased at a good clip over the past decade, and there's reason to expect more growth to come. Cystic fibrosis patients now live longer than they once did, partly thanks to Vertex's breakthroughs. Unfortunately, they still need constant care. Therefore, its products continue to be in demand among these populations. Furthermore, Vertex is seeking to expand into new territories and develop more effective medicines, particularly for patients who would not benefit from its current treatments. Vertex's core franchise can still experience significant growth. Even if another company succeeds in developing competing cystic fibrosis therapies, the biotech's first-mover advantage and its relationship with patients, physicians, and third-party payers give it a leg up. Vertex has also expanded its portfolio with the approval of products such as Journavx for acute pain and Casgevy for beta-thalassemia and sickle cell disease. Its pipeline should yield more clinical and regulatory wins within the next two years. Vertex is an innovative biotech company with an incredibly strong underlying business. Beyond the company's dominance in cystic fibrosis, that's the core reason to buy the stock. It should deliver excellent results over the long term. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Berkshire Hathaway and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Berkshire Hathaway and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 2 Top Stocks to Buy Right Now was originally published by The Motley Fool
Globe and Mail
3 days ago
- Business
- Globe and Mail
2 Top Stocks to Buy Right Now
Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks are likely to produce superior returns to most other assets over the next decade, as they have consistently done in the past. Moreover, when things are erratic, it can be a wise strategy to invest in companies that are positioned to perform well over the long term. Two great examples are Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). 1. Berkshire Hathaway Warren Buffett's recent announcement that he would step down from his longtime role as the CEO of Berkshire Hathaway by the end of this year will almost certainly come down as one of the most talked-about pieces of news on Wall Street this year. In the wake of that leadership change, some investors may decide to steer clear of the stock. After all, it was Buffett who led the conglomerate to market-crushing returns over the decades, not Greg Abel, his chosen successor. Further, Buffett is leaving at an unsteady time economically. Corporations are facing a rapidly shifting global trade environment. Macroeconomic troubles appear likely to take a toll on many companies, even those as strong as Berkshire Hathaway. Can Abel successfully take the reins of the conglomerate, especially at a time like this? In my view, the answer is yes. Buffett might be irreplaceable, but he leaves behind an incredibly robust and diversified business. Between Berkshire Hathaway's several dozen subsidiaries across an array of sectors and industries, its impressive stock portfolio, and its massive cash stockpile, it's positioned to handle severe economic shocks better than most companies. Not all of the company's businesses will be affected equally by macro turbulence. Some might thrive as others suffer -- it will average out, at least somewhat. Berkshire Hathaway might not come out of a recession (if one is on the way) completely unscathed, but it will come out on solid footing. And regarding the pending change in management, Buffett did not pick Abel out of a hat. As a top executive of the conglomerate, Abel has soaked up Buffett's investment philosophy, and he has been capably overseeing a large portion of the company for years. Nor will Abel be doing the job alone, any more than Buffett did it by himself. Many of Berkshire Hathaway's executives have been with the company for a long time and have contributed significantly to it achieving its current status as one of the few corporations with a trillion-dollar-plus market cap. The stock should continue to deliver superior returns in the long run under new management. That's why it's still worth investing in today. 2. Vertex Pharmaceuticals Vertex Pharmaceuticals' shares recently plunged after it announced its fiscal second-quarter results. Those were unimpressive, partly due to a non-cash impairment charge it took relating to an investigational medicine it is no longer pursuing, and partly due to the illegal sales of knock-off versions of its patented drugs in Russia, which took a slice out of its total revenues. However, these are relatively minor issues, at least when viewed in the broader context. Vertex remains the undisputed leader in cystic fibrosis therapies. This rare lung disease only affects about 94,000 patients in Vertex's core markets of North America, Europe, and Australia. But since it sells the only medicines that target the underlying causes of the condition, Vertex has substantial pricing power. That's why revenue and earnings have consistently increased at a good clip over the past decade, and there's reason to expect more growth to come. Cystic fibrosis patients now live longer than they once did, partly thanks to Vertex's breakthroughs. Unfortunately, they still need constant care. Therefore, its products continue to be in demand among these populations. Furthermore, Vertex is seeking to expand into new territories and develop more effective medicines, particularly for patients who would not benefit from its current treatments. Vertex's core franchise can still experience significant growth. Even if another company succeeds in developing competing cystic fibrosis therapies, the biotech's first-mover advantage and its relationship with patients, physicians, and third-party payers give it a leg up. Vertex has also expanded its portfolio with the approval of products such as Journavx for acute pain and Casgevy for beta-thalassemia and sickle cell disease. Its pipeline should yield more clinical and regulatory wins within the next two years. Vertex is an innovative biotech company with an incredibly strong underlying business. Beyond the company's dominance in cystic fibrosis, that's the core reason to buy the stock. It should deliver excellent results over the long term. Should you invest $1,000 in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Business Insider
4 days ago
- Business
- Business Insider
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)
BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $557.00. The company's shares closed today at $441.97. Confident Investing Starts Here: According to TipRanks, Seigerman is a 4-star analyst with an average return of 3.7% and a 43.73% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Novo Nordisk, and Vertex Pharmaceuticals. In addition to BMO Capital, Vertex Pharmaceuticals also received a Buy from UBS's Eliana Merle in a report issued yesterday. However, today, Barclays maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
India Today
6 days ago
- Business
- India Today
5 Indian-origin, one Indian national on Fortune's 2025 Most Powerful Women list
Indian-Americans Reshma Kewalramani, Bela Bajaria, Revathi Advaithi, and Meena Lakdawala Flynn, along with India-based Roshni Nadar Malhotra and UK-based Leena Nair, are among the leading women in the global business Kewalramani, CEO of Vertex Pharmaceuticals, ranked 18th for her groundbreaking work in biopharma. Roshni Nadar Malhotra, ranked 21st, leads HCL Technologies and champions education and conservation in chief content officer, Bela Bajaria, at 31st, oversees a massive content empire. Revathi Advaithi, ranked 62nd, drives innovation at manufacturing giant Flex. Meena Flynn, at 69th, steers Private Wealth Management at Goldman Sachs, focusing on client growth and advancing women in Here's a closer look at their KEWALRAMANI, RANK: 18Reshma Kewalramani, the Indian-origin CEO of US-based Vertex Pharmaceuticals, ranked 18th on the a licenced doctor, became Vertex Pharmaceuticals' CEO in 2020. She was previously the biopharma company's chief medical biopharma company, valued at over $110 billion, is a major player in discovering, developing and producing innovative medicines. The company is best known for developing multiple novel drug combinations to treat cystic fibrosis, which affects 1,00,000 people globally, according to Mumbai-born CEO moved to the US in 1988. She pursued a career in medicine, earning her degree from Boston University, followed by a fellowship at Massachusetts General also clinched a spot in TIME magazine's 100 Most Influential People of 2025, notably the only person of Indian NADAR MALHOTRA, RANKS: 21advertisementRanked 21st on the list, Roshni Nadar Malhotra, chairperson of HCL Technologies, has become India's richest woman — and the country's third-richest individual overall — following a transfer of shares from her father, Shiv a career in TV news, Malhotra returned to the family business in 2008. She rose to chair in 2020, looking after the company's broader strategic initiatives. In addition to her position as HCL Tech's chairperson, Malhotra is also involved in philanthropic efforts, including providing education for gifted students in rural India, and work in nature conservation, Fortune hopes to see more women in India's fast-growing tech sector. "We want more women to build long-term careers in tech," she told Fortune India earlier this 2024, she made it to Forbes's 100 Most Powerful Women list. She was ranked 81 last BELA BAJARIA, RANK: 31Indian-American Bela Bajaria, who secured 31st spot in the list, is Netflix's chief content officer. She oversees an annual content budget of over $17 billion for the OTT joined Netflix from Universal Television in 2016 as head of unscripted and scripted content, before becoming the chief content officer in has helped turn Netflix into an international entertainment giant while pushing the near-$500 billion company into live events and sports, inking deals with WWE and the NFL, Fortune in London to Indian immigrant parents, she won Miss India Worldwide in 1991. During her tenure, Netflix has frequently earned more Emmy and Oscar nominations than any other MEENA FLYNN Ranks 69Leena Nair, ranked 45, became the global CEO the French luxury fashion house Chanel in 2021 — the first woman of colour to hold the is also among the few women of colour leading a global luxury brand. Under her leadership, the 115-year-old family-controlled brand has bucked the luxury slowdown affecting its rivals by delivering a 16% increase in revenues in 2023, worth $20 in her tenure, Nair increased the funding of Chanel's charity, Foundation Chanel, to $100 million to support women's and girls' safety and economic comes from Maharashtra's Kolhapur, and climbed to the top position from modest REVATHI ADVAITHI RANKED 62 IN THE LISTRanked 62, Revathi Advaithi has led manufacturing giant Flex for past six years, with a strong focus on investing in data centre her leadership, the company's data centre business had year-over-year growth of 45% in Q4 of Calendar Year oversees more than 1,40,000 employees in 30 countries. She also sits on the boards of Uber, and the MIT Presidential CEO Advisory holds a bachelor's degree in mechanical engineering from the Birla Institute of Technology and Science (BITS), Pilani. She later earned an MBA in international business from the Thunderbird School of Global Management in the MEENA FLYNN, RANKED 69Ranked 69, Meena Flynn, co-head of global Private Wealth Management, has led that charge at Goldman Sachs, with impressive results. Goldman Sachs Wealth Management, including Private Wealth Management, oversees more than $1 trillion in assets globally, and generated over $5 billion in management and other fees last year, up 11% from 2023 and a record for the co-head of the One Goldman Sachs initiative, Flynn is also tasked with forging deeper relationships with around 100 of the firm's wealthiest clients, who collectively account for almost 20% of Goldman's revenue. A newcomer on this year's list, Flynn has championed women in her role, and the majority of the firm's global PWM partners are women, according to resides in New York City with my two children and husband, as per Forbes. She holds a bachelor's degree in economics from The George Washington University. advertisement
Yahoo
27-05-2025
- Business
- Yahoo
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth. The 10 therapeutics stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.2%. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 9% since the latest earnings results. Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Myriad Genetics reported revenues of $195.9 million, down 3.1% year on year. This print fell short of analysts' expectations by 2.3%. Overall, it was a softer quarter for the company with full-year revenue guidance missing analysts' expectations. 'We had a challenging first quarter of 2025 with strength in our prenatal and oncology MyRisk tests offset by softness in GeneSight and unaffected hereditary cancer tests. While we are actively working on initiatives to re-accelerate testing volumes, this will take time; therefore we are lowering our 2025 financial guidance. We are taking immediate steps to reduce overall expenditures while prioritizing investment in new product development and programs intended to drive revenue growth,' said Sam Raha, President and CEO, of Myriad Genetics. Unsurprisingly, the stock is down 45% since reporting and currently trades at $3.99. Read our full report on Myriad Genetics here, it's free. Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments. United Therapeutics reported revenues of $794.4 million, up 17.2% year on year, outperforming analysts' expectations by 5.6%. The business had a very strong quarter with a narrow beat of analysts' EPS estimates. However, the results were likely priced into the stock as it's traded sideways since reporting. Shares currently sit at $302.50. Is now the time to buy United Therapeutics? Access our full analysis of the earnings results here, it's free. Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management. Vertex Pharmaceuticals reported revenues of $2.77 billion, up 3% year on year, falling short of analysts' expectations by 2.3%. It was a disappointing quarter as it posted a significant miss of analysts' EPS estimates. As expected, the stock is down 13.1% since the results and currently trades at $434.31. Read our full analysis of Vertex Pharmaceuticals's results here. Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. AbbVie reported revenues of $13.34 billion, up 8.4% year on year. This number beat analysts' expectations by 3.3%. Overall, it was a very strong quarter as it also logged a solid beat of analysts' constant currency revenue estimates and a decent beat of analysts' EPS estimates. The stock is up 1.5% since reporting and currently trades at $183.25. Read our full, actionable report on AbbVie here, it's free. Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children. BioMarin Pharmaceutical reported revenues of $745.1 million, up 14.8% year on year. This result topped analysts' expectations by 1%. It was a strong quarter as it also put up a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. BioMarin Pharmaceutical delivered the highest full-year guidance raise among its peers. The stock is down 8.3% since reporting and currently trades at $57.56. Read our full, actionable report on BioMarin Pharmaceutical here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
